Antibiotice S.A.

ATB

ROATBIACNOR9

Pharmaceuticals

End-of-day quote Bucharest S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
1.935 ^RON	+0.26%		0.00%	+38.71%

Feb. 28	Antibiotice S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Antibiotice S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Antibiotice Announces Earnings Results for the First Half Ended June 2017

August 17, 2017 at 07:35 am EDT

Antibiotice announced earnings results for the first half ended June 2017. For the first half, net profit rose 17% year-on-year, reaching RON 19.2 million. Sales increased by an annual 2% to RON 147.2 million.

Latest news about Antibiotice S.A.

Antibiotice S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Antibiotice S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Antibiotice S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-14	CI
Antibiotice S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Antibiotice S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-23	CI
Antibiotice S.A. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-11-10	CI
Antibiotice S.A. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-15	CI
Antibiotice S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-12	CI
Antibiotice S.A. Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-27	CI
Antibiotice S.A. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-11-11	CI
Antibiotice S.A. Reports Earnings Results for the Half Year Ended June 30, 2021	21-07-25	CI
Antibiotice S.A. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-11	CI
Antibiotice S.A. Reports Earnings Results for the Full Year Ended December 31, 2020	21-02-25	CI
Antibiotice S.A. Reports Earnings Results for the Nine Months Ended September 30, 2020	20-11-11	CI
Antibiotice S.A. Reports Earnings Results for the Half Year Ended June 30, 2020	20-08-13	CI
Antibiotice S.A. Reports Earnings Results for the Full Year Ended December 31, 2019	20-02-26	CI
Antibiotice S.A. Reports Earnings Results for the Nine Months Ended September 30, 2019	19-12-10	CI
Antibiotice S.A. Reports Earnings Results for the Half Year Ended June 30, 2019	19-08-09	CI
Antibiotice S.A. Reports Earnings Results for the First Quarter Ended March 31, 2019	19-05-14	CI
Antibiotice S.A. Reports Earnings Results for the Full Year Ended December 31, 2018	19-02-28	CI
Antibiotice S.A. Reports Earnings Results for the Year Ended December 31, 2017	18-02-13	CI
Antibiotice lasi Announces Earnings Results for the Nine Months of 2017	17-11-14	CI
Antibiotice Announces Earnings Results for the First Half Ended June 2017	17-08-17	CI
Antibiotice S.A Reports Sales Results for the First Quarter of 2016	16-07-31	CI
Antibiotice Reports Earnings Results for the First Quarter of 2016	16-05-13	CI

Chart Antibiotice S.A.

Duration

Period

More charts

Company Profile

Antibiotice SA is a Romania-based company primarily active in the pharmaceutical industry. The Company manufactures drugs in five pharmaceutical forms: powder for injectable solutions and suspensions, capsules, tablets, suppositories and preparations. The Company's products are designed to treat a range of diseases, including infectious, dermatology, cardiovascular, digestive and musculoskeletal system related. The Company operates eight certified production lines. Its portfolio includes products for human and veterinary use, pharmaceutical ingredients and biological fertilizers. Additionally, the Company is engaged in the research and development activities.

Sector

Pharmaceuticals

Calendar

2024-09-22 - Ex-dividend day for final dividend

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ANTIBIOTICE S.A.	+38.71%	279M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B